Poster Presenter: Punith Chirumamilla, MD, Internal Medicine Resident, Baptist Memorial Hospital-North Mississippi
Poster Title: Comparative Efficacy and Safety of IL-17 Inhibitors Versus Adalimumab in Biologic-Naive Psoriatic Arthritis Patients: A Meta-Analysis of Randomized Controlled Trials
Poster Session C: 10:30 a.m.–12:30 p.m. on Tuesday, October 28
What is your poster about?
“It’s a meta-analysis comparing interleukin-17 (IL-17) inhibitors and adalimumab in biologic-naïve psoriatic arthritis patients, focusing on both efficacy and safety.”
Why did you decide to investigate this topic?
“IL-17 inhibitors and adalimumab are two of the most common first-line biologics in psoriatic arthritis, but head-to-head data are scarce. I wanted to take a closer look at how they compare, to help make treatment decisions clearer and more patient-focused.”
What are you working on next related to this research?
“I’m currently exploring emerging treatment options and advances in rheumatoid arthritis to better understand where the field is heading.”
What excites you most about your work?
“That it has the potential to guide treatment decisions and make care more personalized for patients.”
What are you most looking forward to at ACR Convergence 2025 in Chicago?
“I’m looking forward to connecting with experts, fellows, and residents, gaining diverse perspectives on where rheumatology is heading, and learning about the latest advances. I also hope to receive feedback on my work and build collaborations that can shape my future research.”
There’s Still Time to Register for ACR Convergence 2025
If you haven’t registered for ACR Convergence 2025, register today to participate in this year’s premier rheumatology experience, October 24–29 in Chicago. All registered participants receive on-demand access to scientific sessions after the meeting through October 31, 2026.